Drug design based on degradation-resistant, long-acting Glucagon-like peptide-1 receptor (GLP-1R)
agonists for treating type 2 diabetes is attracting a lot of attention. Here, the authors have examined in detail
how in silico drug design is aiding in developing novel GLP-1 receptor agonist drugs. Their pharmacotherapy
and adverse effects have also been summarized. After the analysis of currently available information on this
topic, the authors feel that in silico method is a great auxiliary tool in almost all the experimental studies on
GLP-1 receptors and is highly efficient in identifying novel drug molecules that can act as GLP-1 receptor agonists.
Keywords: GLP-1, Type 2 diabetes mellitus (T2DM), GLP-1 receptor agonists, In Silico, CADDD, molecular docking, drug design.
Rights & PermissionsPrintExport